Parkman Healthcare Partners LLC Buys 159,341 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Parkman Healthcare Partners LLC grew its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 34.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 625,749 shares of the company’s stock after acquiring an additional 159,341 shares during the period. Day One Biopharmaceuticals accounts for 1.3% of Parkman Healthcare Partners LLC’s holdings, making the stock its 26th biggest holding. Parkman Healthcare Partners LLC’s holdings in Day One Biopharmaceuticals were worth $9,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Quest Partners LLC bought a new position in Day One Biopharmaceuticals in the 4th quarter worth about $29,000. Amalgamated Bank grew its stake in Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after acquiring an additional 2,554 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Day One Biopharmaceuticals by 352.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after purchasing an additional 7,841 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $156,000. 87.95% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $16.01, for a total transaction of $160,100.00. Following the sale, the insider now owns 1,184,662 shares in the company, valued at $18,966,438.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, General Counsel Adam Dubow sold 3,253 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $52,308.24. Following the sale, the general counsel now owns 21,731 shares in the company, valued at $349,434.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total transaction of $160,100.00. Following the completion of the sale, the insider now owns 1,184,662 shares in the company, valued at approximately $18,966,438.62. The disclosure for this sale can be found here. Insiders sold a total of 185,534 shares of company stock valued at $3,236,030 over the last 90 days. Insiders own 8.40% of the company’s stock.

Analyst Upgrades and Downgrades

DAWN has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. The Goldman Sachs Group dropped their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. JPMorgan Chase & Co. increased their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Finally, Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Day One Biopharmaceuticals Trading Down 0.6 %

Shares of NASDAQ DAWN traded down $0.08 during midday trading on Thursday, reaching $12.92. The company had a trading volume of 666,519 shares, compared to its average volume of 869,737. The business’s 50-day simple moving average is $14.82 and its 200 day simple moving average is $14.65. The stock has a market cap of $1.13 billion, a P/E ratio of -5.15 and a beta of -1.53. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). Analysts predict that Day One Biopharmaceuticals, Inc. will post -2.69 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.